['lymphoma, large b-cell, diffuse']
['durvalumab', 'rituximab', 'doxorubicin', 'vincristine', 'cyclophosphamide', 'prednisone', 'lenalidomide']

        Inclusion Criteria:

          1. CD20+Diffuse Large B-Cell Lymphoma.

          2. Ann Arbor stage 3 or 4 or stage 2 with bulky disease

          3. High or high-intermediate disease risk.

          4. No prior anti-lymphoma treatment.

          5. Subject is willing and able to undergo biopsy.

          6. Investigator considers R-CHOP immunochemotherapy appropriate.

          7. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

          8. Adequate hematology laboratory results (absolute neutrophil count ≥ 1.5 * 10^9/L,
             platelet count ≥ 75 * 10^9/L, hemoglobin ≥ 10.0 g/dL).

          9. Adequate biochemistry laboratory results (aspartate aminotransferase (AST/SGOT) and
             alanine aminotransferase (ALT/SGPT) ≤ 3.0 * upper limit of normal; bilirubin ≤ 2.0
             mg/dL; creatinine clearance of ≥ 40 mL/min).

         10. Bi-dimensionally measurable disease (> 2.0 cm).

         11. Subject is using effective contraception.

        Exclusion Criteria:

          1. Diagnosis of lymphoma other than Diffuse Large B-Cell Lymphoma.

          2. Composite lymphoma or transformed lymphoma.

          3. Primary or secondary Central Nervous System involvement by lymphoma.

          4. Seropositive or active viral infection with hepatitis B virus, human immunodeficiency
             virus or hepatitis C virus.

          5. History of other malignancies, unless disease-free for ≥ 5 years.

          6. Left ventricular ejection fraction < 50%.

          7. Peripheral neuropathy ≥ Grade 2.

          8. Prior use of lenalidomide, or monoclonal antibodies against CTLA-4, PD-1, or PD-L1.

          9. High risk of developing thromboembolic events, who are unwilling to take venous
             thromboembolism prophylaxis.

         10. Active or prior documented autoimmune or inflammatory disorders within the past 3
             years.

         11. Current or prior use of immunosuppressive medication within 28 days before start of
             treatment.
      